High quality well-characterized antibodies and antigens for cell biology and biomedical research, including oncology and stem cell research, for use in cancer diagnosis.

Welcome at MUbio Products BV.

MUbio Products bv (MUbio)develop and manufacture high quality antibody reagents for cell biology and biomedical research, including cancer and stem cell research. All products are manufactured according to strict ISO 9002 quality guidelines and are available in quantities ranging from 0.1 mg to larger bulk amounts upon request.

MUbio’s products are used in a number of proprietary and partnered development programs investigating, testing and validating patented antibodies and antigens for diagnostic applications and vaccination strategies in the field of lung cancer. 

MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory.

MUbio's partnered and proprietary R&D projects focus on the:

• the identification and validation of cancer biomarkers
• development of lung cancer diagnostic kits
• research and development of a lung cancer vaccine

Antibody Range

  • Cell Adhesion Proteins

    • NCAM
    • Cadherins
    • Catenins
    • Integrins
    • Plakophilins
    • Selectins
  • Cell Cycle Markers

    • Cell Cycle Related Markers
  • Cytoskeletal Proteins

    • Cytokeratins
    • Vimentin and Desmin
    • Glial Fibrillary Acidic Protein (GFAP)
    • Neurofilaments
    • Lamins
    • Actin
    • Smoothelin
  • Extracellualr Matrix Proteins

    • Entactin/Nidogen
    • Fibronectin
    • Lamins
  • Filamentous Phage Coat Proteins

    • g8p-protein
  • Membrane Proteins

    • Reticulons
    • Cardiotin
  • Nuclear Proteins

    • Lamins

Contact us for more info >>

 
 
 
© 2008 STRATECH | DISCLAIMER | PRIVACY
PHONE:
 
FAX: 
+61 (0)2 9973 2421
 
+61 (0)2 9012 0019
 
Web Design Gold Coast | Snowball Internet.        Powered by webEFEKTs.